CytoAgents
PITTSBURGH, PA · Biotechnology · 10 employees
CytoAgents, Inc. is a clinical-stage therapeutics company developing CTO1681, an oral, steroid sparing immunomodulator for multiple indications driven by cytokine inducing inflammation. By effectively reducing the inflammation in the tumor microenvironment and preventing life-threatening toxicities caused by overwhelming inflammation, CytoAgents is working to enable safer, widescale adoption of th
Funding history
- Funding Round — $2.3M — Oct 2025
- Funding Round — $7.0M — May 2023
- Funding Round — $6.1M — Aug 2021
Recent signals
- Dec 16, 2025: CytoAgents Appoints Dr. Johannes Wolff as Chief Medical Officer and Michael Howell as Chief Scientific Officer
- Oct 01, 2025: Raised $2.3M
- May 16, 2023: Raised $7.0M
- Aug 12, 2021: Raised $6.1M
See plans & pricing → Track CytoAgents’s funding, hiring, and signals — with verified contacts — on Fundz.